Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome

checkorphan
Learn more about:
Adenomyosis
Related Clinical Trial
Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With Endometriosis and or Adenomyosis The Effect of Adenomoyosis on Pregnancy Outcomes Observational Study of Patients Suffering From Endometriosis and Adenomyosis Factors Associated With Adenomyosis and a Clinical Scoring System for the Diagnosis Quality of Life After Hysterectomy (AdenoQOL) Low Molecular Weight Heparin on the Adenomyosis Patients’IVF-ET Outcome Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI Clinical and Molecular Study of Endometriosis and Adenomyosis Surgical Success After Laparoscopic vs Abdominal Hysterectomy Electronic Catheter Stethoscope Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Uterine Artery Embolization for Symptomatic Fibroids Oxytocin in MRI-HIFU To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Effect of Addition of Steroids on Duration of Analgesia Paracervical Block in Laparoscopic Hysterectomy Use of Dexamethasone in Uterine Artery Embolization Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Dienogest for Treatment of Adenomyotic Uteri Health-Related QoL Among Women Receiving Hysterectomy in NTUH Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis Adenomyosis and Ulipristal Acetate Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis LNG-IUS for Treatment of Dysmenorrhea Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Adenomyosis: Genomic Mechanisms and Biological Response What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis A Prospective Study of Diagnostic Accuracy of Ultrasound Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis A Multi-omics Study of Adenomyosis Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis Levonorgestrel Intrauterine System and Adenomyosis Validation of the Adenomyosis Calculator Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis Norwegian Adenomyosis Study III: Peristalsis Histopathological Diagnosis of Adenomyosis Norwegian Adenomyosis Study I Vaginal Bromocriptine for Treatment of Adenomyosis Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis

Brief Title

Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome

Official Title

To Study the Effect of Low Molecular Weight Heparin on the Adenomyosis Patients'Outcome of in Vitro Fertilization-embryo Transplantation

Brief Summary

      In assisted reproductive technology, adenomyosis patients are characterized by lower clinical
      pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study
      is to explore whether low molecular weight heparin can reduce the abortion rate of
      adenomyosis patients in frozen thawed embryo transfer cycles.

Study Type

Interventional

Primary Outcome

Early spontaneous abortion rate

Condition

Adenomyosis

Intervention

Low molecular weight heparin

Study Arms / Comparison Groups

 Control Group
Description:  Adenomyosis patients in control group have normal luteal progesterone support.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

70

Start Date

February 1, 2020

Completion Date

January 31, 2022

Primary Completion Date

January 31, 2022

Eligibility Criteria

        Inclusion Criteria:

          1. The basal serum level of FSH was less than 10 IU / L

          2. Diagnosed with adenomyosis by ultrasound

          3. The first frozen thawed embryo transfer cycle, by hormone replacement protocol

          4. Transfer at least one high quality frozen embryo;

          5. Patients agreed to use low molecular weight heparin after FET, and they were able to
             sign informed consent in person.

        Exclusion Criteria:

          1. With abnormal karyotype;

          2. Accompanied with other uterine diseases: intrauterine adhesion, intramural myoma,
             moderate to severe endometriosis, congenital uterine malformation, endometrial
             tuberculosis, thin endometrium < 8mm on the day of transformation, etc;

          3. PCOS, RIF patients;

          4. There are indications of conventional anticoagulation or antiplatelet therapy, such as
             antiphospholipid syndrome, autoimmune diseases, coagulation dysfunction, etc;

          5. There were contraindications to hormone replacement therapy and low molecular weight
             heparin;

          6. Participating in other clinical studies;

          7. Unable to follow-up

Gender

Female

Ages

20 Years - 38 Years

Accepts Healthy Volunteers

No

Contacts

, ,

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT04741295

Organization ID

SZ-2021-ADE1

Responsible Party

Principal Investigator

Study Sponsor

Nanjing University

Study Sponsor

, ,

Verification Date

February 2021